Replies to post #709996 on NorthWest Biotherapeutics Inc (NWBO)

[improving]

No idea why you are here, except to bash the company. It's a tough call, but I'll continue to go with management's guidance over yours.
You should take all of your followers (two I believe) and move on.
Peace.

[Doc logic]

Investor082,

All those who will want to get out had a chance to vote at the ASM. Barely any budge off of previous vote counts so show me the impact of those who will choose to get out early other than to help some others cover short positions or take up new long positions in a company that will be the future of cancer treatment while those who bail will miss out unless you are simply talking about a timed trading strategy that anticipates no additional backup news for a while. In that case that trade is just a calculated risk, not a permanent exit; ).
I would love to see the 7 market makers kept out of the action by the time approval is announced and a big investor step up between now and then to benefit from NWBO’s new position with an approved treatment to help leverage a likely partnership deal that might otherwise be held up by unfavorable terms because NWBO doesn’t have financial stability in place for its investors. Then I would love to see what happens with other big pharma offers once Flaskworks comes on line enough to be used in trials. Once financing is taken care of I would love to see what improved DCVax Direct does in months instead of years and who wouldn’t love to see the tables turn as big pharma attempts at catching up fall short and they find themselves needing to approach NWBO as talent gets drawn away from them and to the new cancer treatment leader. Yep, lots of good reasons to stick around for the show because having a big checkbook will definitely come in handy if anyone wants a part of what is coming sooner or later depending on the moves by those with the money. Best wishes.

[Doc logic]

Investor082,

Optimizing an already acceptable GMP designed unit and getting multiples installed inspected and passed for equivalence isn’t going to take forever and use in trials can happen before full commercial validation.
A partner certainly could be announced at approval and it will likely be tied to Flaskworks development but may delay major funding until Flaskworks validation to incentivize final steps but also help prevent more rapid development of Direct. The slow down of Direct development as a strategy may have changed now for Merck and BMY since their new versions of checkpoint inhibitor administration come with an increased risk of death. This situation likely pushes them to want to develop Direct more quickly into an approved and commercially available product as their inhibitors may be left to face generic competition. The issue this creates is that they will be reduced more into the role of banker and book keepers rather than true development partner as Direct will be in a very advanced state of development by the time they come on board and all that is left is integration of supply chain, assuring manufacturing capacity and then distribution which Walgreens is already preparing for as the approval of L approaches.
Big pharmas are definitely going to be evaluating when they need to make their moves as marketing approval and Flaskworks validation approach for NWBO. There will not likely be as much time between these two events as many anticipate and any favorable decision for NWBO with the spoofing litigation raises awareness to a whole new level. If this comes near approval everyone will realize what this means for the perps and NWBO recognition as the true threat to big pharma that it is. Awareness about what Flaskworks means and Direct capturing the attention and imagination of the masses will create some fireworks that big pharmas will definitely want to be linked to by then or be left behind. Best wishes.